WT, bm1, and bm12 mature BMDCs present H2Db-restricted gp10025–33 peptide to CD8+ T cells similarly, but the bm12 BMDC vaccine is superior in delaying B16-F10 tumor growth and improves antigen-specific CD8+ T cell responses and proinflammatory Th1 responses. This evidence concerns the gene CD8A and neoplasm.